Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.
about
Role of isavuconazole in the treatment of invasive fungal infectionsNew and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapyFacts, fancies and follies of drug-induced QT/QTc interval shortening.QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac RepolarizationA Comparative Study between Olanzapine and Risperidone Regarding Drug-Induced Electrocardiographic Changes.Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen.Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicityOlanzapine induced Q-Tc shortening.How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.Studying semblances of a true killer: experimental model of human ventricular fibrillation.Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide.Mechanisms of drug-induced proarrhythmia in clinical practice.Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes.Different sensitivity to the suppressive effects of isoflurane anesthesia on cardiorespiratory function in SHR/Izm, WKY/Izm, and Crl:CD (SD) rats.Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignanciesReducing QT liability and proarrhythmic risk in drug discovery and development.Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.HERG1 channel agonists and cardiac arrhythmia.Stem cells and their derivatives: a renaissance in cardiovascular translational research.Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel.Alterations of Blood Pressure and ECG following Two-Week Consumption of Berberis integerrima Fruit Extract.Novel targets and regulatory ordeal by QT interval.QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus.A Randomized, Placebo- and Positive-Controlled, Single-Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects.Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3.
P2860
Q26740837-A291398B-2AF9-42EA-A2DC-781C7B4B12C5Q27007942-AD2DB9BA-EAD7-476B-B753-5B7622B235FEQ33661036-F495D4DB-9F3A-44F8-AD5E-5567255E0DE5Q33837720-A1B98030-CB83-4CE0-B20C-8665FFFF1AEDQ34243053-9F651BBE-5E4E-4E0D-BA76-D848D2E9395BQ34336897-BEB02CAC-67DC-4350-B15E-6B4DA0752A92Q34407398-D70758B2-5191-4772-B106-20F1E2595EADQ34462136-E7C5B816-8658-4DB8-AC95-8ED9E51BB9ABQ34631498-F46F7AB7-A234-47C8-A265-CE2BD68328FBQ34642834-9E3BED27-63E5-4433-9C2D-15A9C779842FQ35036150-73DDC617-2F96-4187-B717-7B21873ACABBQ35191408-20A79AE7-9732-4D82-A8C4-EA2FA5309626Q35900903-0F93ACEE-4E36-4884-A1F8-F8234F314CD8Q36351042-2DE00A43-9363-47A9-A97C-60313C6456C8Q37001536-9EF7FE7F-E1BE-47A3-A6DF-CF47F22797CEQ37143372-5E2EB734-6ABA-496D-B9CB-DBE26D9CF072Q37418203-33991004-236B-4152-A75A-21279ACED8BBQ37599345-0696B7CF-22A9-4D3A-B773-C87E02A0FD01Q37689199-3C55A0A5-AA5F-422E-89D2-8EC39D5EAAE5Q37689204-DC590A81-9459-45E8-A664-58BD50EE2A30Q37699209-2FC2991D-170D-48F3-A158-E0B748FD5850Q37808135-A709FA74-9AD5-4E49-8BA5-CC6EDD492E94Q38770432-DF852B0F-9CCF-48FD-AD74-2E3F67E59276Q38909233-E237C760-F9E5-4125-9FAC-6D95A3F1BA39Q39649820-D2A1E0FE-C0AC-4D5E-98E6-37605A9F58F9Q39871284-58C4FE60-E32E-47E1-80D1-C4F7CBD220A9Q43024693-E29C4F5B-7ACD-4448-B35C-AF7B045A7A98Q47790423-2DA13FDA-C762-4EB3-8EF0-AEEF27FB715CQ48517340-DED4724C-711D-45B1-B795-B00C59520DF4
P2860
Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Drug-induced QT interval short ...... a and regulatory perspectives.
@ast
Drug-induced QT interval short ...... a and regulatory perspectives.
@en
type
label
Drug-induced QT interval short ...... a and regulatory perspectives.
@ast
Drug-induced QT interval short ...... a and regulatory perspectives.
@en
prefLabel
Drug-induced QT interval short ...... a and regulatory perspectives.
@ast
Drug-induced QT interval short ...... a and regulatory perspectives.
@en
P2860
P1476
Drug-induced QT interval short ...... a and regulatory perspectives.
@en
P2093
Rashmi R Shah
P2860
P356
10.1111/J.1476-5381.2009.00191.X
P407
P577
2009-06-25T00:00:00Z